Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic
  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

Arcturus Therapeutics Announces Fourth Quarter 2022 Financial Update and Pipeline Progress

$200 million upfront payment received in December 2022 from CSL collaboration

Achieved $90 million in development milestones in March 2023 under CSL collaboration

ARCT-154 Phase 3 COVID-19 booster trial enrollment completed in Japan

Multiple patients enrolled in ARCT-810 Phase 2 multiple ascending dose trial for OTC deficiency

ARCT-032 Phase 1 Cystic Fibrosis trial initiated and enrollment of first two cohorts successfully completed

Investor conference call at 4:30 p.m. ET today

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced its financial results for the fourth quarter ended December 31, 2022, and provided corporate updates.

“Arcturus has continued to make remarkable operational and pipeline progress. This was recently exemplified by the completion of the initial objectives with our partnered COVID-19 and Flu vaccine programs with CSL,” said Joseph Payne, President and CEO of Arcturus Therapeutics. “We are also pleased to report the completion of full enrollment ahead of schedule in the Phase 3 study being conducted by Meiji Pharma to evaluate ARCT-154 as a booster vaccine for COVID-19.”

“Within the first four months of our CSL collaboration, we successfully achieved multiple program objectives, triggering $90 million in milestone payments,” said Andrew Sassine, CFO of Arcturus Therapeutics, “Additionally, with the elimination of $33.3 million of non-recourse debt to Singapore, our cash runway now extends into the beginning of 2026.”

Recent Corporate Highlights

  • In December 2022, the Company received a $200 million upfront payment associated with the exclusive global collaboration and license agreement with CSL Seqirus, for the research, development, manufacture, and commercialization of next generation mRNA vaccines. Arcturus is eligible to receive up to $4.3 billion in potential development and commercial milestones if all products are registered in the licensed fields, 40% profit sharing for COVID-19 vaccines and up to low double-digit royalties on influenza vaccine revenues.
  • Arcturus achieved development milestones in March 2023, including milestones associated with nominating next generation vaccine candidates, resulting in $90 million invoiced to CSL Seqirus.
  • In December 2022, the Company announced an agreement with Meiji Pharma to conduct a Phase 3 comparative study to evaluate the safety and immunogenicity of ARCT-154, a self-amplifying mRNA vaccine, as a booster for COVID-19. The ARCT-154 Phase 3 non-inferiority study, now fully enrolled, is being conducted in Japan to compare the immunogenicity of ARCT-154 to Comirnaty® (Pfizer/BioNTech) in over 800 adult participants. Meiji Pharma and the Japanese government are funding the study.
  • ARCT-810, the Company’s mRNA therapeutic candidate for OTC deficiency, is being evaluated in a Phase 2 study, presently enrolling up to 24 adolescents and adults with OTC deficiency. The Phase 2 study is being conducted in the UK and Europe and 9 sites in 6 countries have been activated to date. Multiple patients have been enrolled. The study is designed to evaluate two dose levels and allow for six (6) bi-weekly administrations for each participant. The Company expects to share interim Phase 2 data on a subset of participants later in 2023.
  • ARCT-032, the Company’s inhaled mRNA therapeutic for cystic fibrosis, has advanced to a Phase 1 study, presently enrolling up to 32 participants in New Zealand. The primary objective of this study is to assess safety and tolerability at four (4) dose levels. The first two cohorts have been dosed successfully with no significant adverse events reported to date. The Company expects to complete the full 32 subject study enrollment in Q2 2023.
  • Arcturus will present LUNAR-HBV pre-clinical gene editing mRNA platform data for Hepatitis B Virus on April 27, 2023, at the 18th annual Global Hepatitis Summit Conference in Paris, France.

Financial Results for Fourth Quarter and Year Ended December 31, 2022

Revenues in conjunction with strategic alliances and collaborations: Arcturus’ primary sources of revenues were from license fees, consulting and related technology transfer fees, reservation fees and collaborative payments received from research and development arrangements with pharmaceutical and biotechnology partners. For the three months ended December 31, 2022, the Company reported revenue of $160.3 million compared with $5.8 million for the three months ended December 31, 2021, and $13.4 million for the three months ended September 30, 2022. Total revenue for the year ended December 31, 2022, was $206.0 million compared with $12.4 million for the year ended December 31, 2021. The increase in fourth quarter and year-over-year revenues primarily relates to the $200 million upfront payment we received from the CSL transaction.

Operating expenses: Total operating expenses for the three months ended December 31, 2022, were $38.8 million compared with $43.4 million for the three months ended December 31, 2021, and $50.2 million for the three months ended September 30, 2022. The decline in operating expenses when compared to the three months ended December 31, 2021, was primarily due to lower Covid-19 manufacturing and clinical related expenses. Total operating expenses for the year ended December 31, 2022, were $193.8 million compared with $215.2 million for the year ended December 31, 2021.

Research and development expenses: Research and development expenses for the three months ended December 31, 2022, were $27.0 million compared with $32.6 million for the three months ended December 31, 2021, and $37.7 million for the three months ended September 30, 2022. The decline in research and development expenses when compared to the three months ended December 31, 2021, was primarily due to lower Covid-19 manufacturing and clinical related expenses. Research and development expenses for the year ended December 31, 2022, were $147.8 million compared with $173.8 million for the year ended December 31, 2021.

Net Income: For the three months ended December 31, 2022, Arcturus reported net income of approximately $117.3 million or $4.33 per diluted share, compared with a net loss of $38.7 million, or $1.47 per diluted share in the three months ended December 31, 2021, and a net loss of $35.3 million, or $1.33 per diluted share in the three months ended September 30, 2022. For the year ended December 31, 2022, Arcturus reported a net income of approximately $9.3 million, or $0.35 per diluted share, compared with a net loss of $203.7 million, or $7.74 per diluted share in the year ended December 31, 2021.

Cash Position and Balance Sheet: The Company’s cash balance totaled $391.9 million at December 31, 2022, compared to a cash balance of $370.5 million at December 31, 2021. In March 2023, the Company repaid Singapore $17.1 million which triggered the elimination of $33.3 million in non-recourse debt pertaining to the ARCT-021 program.

Earnings Call: Tuesday, March 28, 2023 @ 4:30 pm ET

Domestic: 1-877-407-0784

International: 1-201-689-8560

Conference ID: 13735876

Webcast: Link

About Arcturus Therapeutics

Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a global late-stage clinical mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR™ mRNA Technology (samRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus’ pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase (OTC) deficiency and cystic fibrosis, along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus’ technologies are covered by its extensive patent portfolio (patents and patent applications issued in the U.S., Europe, Japan, China, and other countries). For more information, visit www.ArcturusRx.com. In addition, please connect with us on Twitter and LinkedIn.

Forward Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact included in this press release, are forward-looking statements, including those regarding strategy, future operations, the likelihood of success of the Company’s pipeline (including ARCT-032 and ARCT-810) and partnered programs (including the COVID-19 and flu programs partnered with CSL Seqirus), the anticipated receipt of $90 million in milestone payments from CSL Seqirus, the period of the Company’s cash runway, the anticipated timing and filing of a J-NDA submission and opportunity for Japanese regulatory PMDA approval of ARCT-154, the sharing of interim Phase 2 data for ARCT-810, the anticipated timing and completion of study enrollment in the ARCT-032 Phase 1 study, the likelihood of success of the collaboration with CSL Seqirus or any collaborations including the achievement of any milestones or other payments, the likelihood that preclinical or clinical data will be predictive of future clinical results, the likelihood that results to date for ARCT-154 or any other clinical candidate will be predictive of future clinical results, the timing and nature of any study results, the likelihood that a patent will issue from any patent application, its current cash position and expected cash burn and the impact of general business and economic conditions. Arcturus may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in any forward-looking statements such as the foregoing and you should not place undue reliance on such forward-looking statements. These statements are only current predictions or expectations, and are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from those anticipated by the forward-looking statements, including those discussed under the heading "Risk Factors" in Arcturus’ most recent Annual Report on Form 10-K, and in subsequent filings with, or submissions to, the SEC, which are available on the SEC’s website at www.sec.gov. Except as otherwise required by law, Arcturus disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.

Trademark Acknowledgements

The Arcturus logo and other trademarks of Arcturus appearing in this announcement, including LUNAR® and STARR™, are the property of Arcturus. All other trademarks, services marks, and trade names in this announcement are the property of their respective owners.

ARCTURUS THERAPEUTICS HOLDINGS INC. AND ITS SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

 

 

 

December 31,

 

September 30,

 

December 31,

(in thousands, except par value information)

 

2022

 

2022

 

2021

Assets

 

 

 

(unaudited)

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

391,883

 

 

$

237,676

 

 

$

370,492

 

Accounts receivable

 

 

2,764

 

 

 

2,044

 

 

 

3,367

 

Prepaid expenses and other current assets

 

 

8,686

 

 

 

6,960

 

 

 

5,102

 

Total current assets

 

 

403,333

 

 

 

246,680

 

 

 

378,961

 

Property and equipment, net

 

 

12,415

 

 

 

11,347

 

 

 

5,643

 

Operating lease right-of-use asset, net

 

 

32,545

 

 

 

33,519

 

 

 

5,618

 

Equity-method investment

 

 

 

 

 

 

 

 

515

 

Non-current restricted cash

 

 

2,094

 

 

 

2,081

 

 

 

2,077

 

Total assets

 

$

450,387

 

 

$

293,627

 

 

$

392,814

 

Liabilities and Stockholders’ Equity

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable

 

$

7,449

 

 

$

17,962

 

 

$

10,058

 

Accrued liabilities

 

 

30,232

 

 

 

25,529

 

 

 

23,523

 

Current portion of long-term debt

 

 

60,655

 

 

 

27,702

 

 

 

22,474

 

Deferred revenue

 

 

28,648

 

 

 

4,656

 

 

 

43,482

 

Total current liabilities

 

 

126,984

 

 

 

75,849

 

 

 

99,537

 

Deferred revenue, net of current portion

 

 

20,071

 

 

 

5,179

 

 

 

19,931

 

Long-term debt, net of current portion

 

 

 

 

 

32,038

 

 

 

40,633

 

Operating lease liability, net of current portion

 

 

30,216

 

 

 

31,218

 

 

 

4,502

 

Other non-current liabilities

 

 

2,804

 

 

 

3,676

 

 

 

 

Total liabilities

 

 

180,075

 

 

 

147,960

 

 

 

164,603

 

Stockholders’ equity:

 

 

 

 

 

 

Common stock: $0.001 par value; 60,000 shares authorized; issued and outstanding shares were 26,555 at December 31, 2022, 26,492 at September 30, 2022 and 26,372 at December 31, 2021

 

 

27

 

 

 

26

 

 

 

26

 

Additional paid-in capital

 

 

608,426

 

 

 

601,129

 

 

 

575,675

 

Accumulated deficit

 

 

(338,141

)

 

 

(455,488

)

 

 

(347,490

)

Total stockholders’ equity

 

 

270,312

 

 

 

145,667

 

 

 

228,211

 

Total liabilities and stockholders’ equity

 

$

450,387

 

 

$

293,627

 

 

$

392,814

 

ARCTURUS THERAPEUTICS HOLDINGS INC. AND ITS SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)

(unaudited)

 

 

 

Three Months Ended

 

 

December 31,

 

September 30,

(in thousands, except per share data)

 

2022

 

2021

 

2022

Revenue:

 

 

 

 

 

 

Collaboration revenue

 

$

160,049

 

 

$

5,794

 

 

$

13,369

 

Grant revenue

 

 

244

 

 

 

 

 

 

 

Total revenue

 

 

160,293

 

 

 

5,794

 

 

 

13,369

 

Operating expenses:

 

 

 

 

 

 

Research and development, net

 

 

26,981

 

 

 

32,633

 

 

 

37,688

 

General and administrative

 

 

11,860

 

 

 

10,806

 

 

 

12,488

 

Total operating expenses

 

 

38,841

 

 

 

43,439

 

 

 

50,176

 

Income (loss) from operations

 

 

121,452

 

 

 

(37,645

)

 

 

(36,807

)

(Loss) gain from equity-method investment

 

 

 

 

 

(156

)

 

 

 

(Loss) gain from foreign currency

 

 

(3,835

)

 

 

(337

)

 

 

1,862

 

Finance expense, net

 

 

1,025

 

 

 

(525

)

 

 

(321

)

Net income (loss) before income taxes

 

 

118,642

 

 

 

(38,663

)

 

 

(35,266

)

Provision for income taxes

 

 

1,295

 

 

 

 

 

 

 

Net income (loss)

 

$

117,347

 

 

$

(38,663

)

 

$

(35,266

)

Earnings (loss) per share:

 

 

 

 

 

 

Basic

 

$

4.43

 

 

$

(1.47

)

 

$

(1.33

)

Diluted

 

$

4.33

 

 

$

(1.47

)

 

$

(1.33

)

Weighted-average shares used in calculation of earnings (loss) per share:

 

 

 

 

 

 

Basic

 

 

26,508

 

 

 

26,359

 

 

 

26,467

 

Diluted

 

 

27,080

 

 

 

26,359

 

 

 

26,467

 

Comprehensive income (loss):

 

 

 

 

 

 

Net income (loss)

 

$

117,347

 

 

$

(38,663

)

 

$

(35,266

)

Comprehensive income (loss)

 

$

117,347

 

 

$

(38,663

)

 

$

(35,266

)

ARCTURUS THERAPEUTICS HOLDINGS INC. AND ITS SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)

 

 

 

Year Ended December 31,

(in thousands, except per share data)

 

2022

 

2021

Revenue:

 

 

 

 

Collaboration revenue

 

$

205,755

 

 

$

12,359

 

Grant revenue

 

 

244

 

 

 

 

Total revenue

 

 

205,999

 

 

 

12,359

 

Operating expenses:

 

 

 

 

Research and development, net

 

 

147,751

 

 

 

173,760

 

General and administrative

 

 

46,071

 

 

 

41,451

 

Total operating expenses

 

 

193,822

 

 

 

215,211

 

Income (loss) from operations

 

 

12,177

 

 

 

(202,852

)

(Loss) gain from equity-method investment

 

 

(515

)

 

 

515

 

(Loss) gain from foreign currency

 

 

(598

)

 

 

584

 

Finance expense, net

 

 

(420

)

 

 

(1,921

)

Net income (loss) before income taxes

 

 

10,644

 

 

 

(203,674

)

Provision for income taxes

 

 

1,295

 

 

 

 

Net income (loss)

 

$

9,349

 

 

$

(203,674

)

Earnings (loss) per share:

 

 

 

 

Basic

 

$

0.35

 

 

$

(7.74

)

Diluted

 

$

0.35

 

 

$

(7.74

)

Weighted-average shares used in calculation of earnings (loss) per share:

 

 

 

 

Basic

 

 

26,445

 

 

 

26,317

 

Diluted

 

 

27,093

 

 

 

26,317

 

Comprehensive income (loss):

 

 

 

 

Net income (loss)

 

$

9,349

 

 

$

(203,674

)

Comprehensive income (loss)

 

$

9,349

 

 

$

(203,674

)

 

Contacts

IR and Media Contacts

Arcturus Therapeutics

Neda Safarzadeh

VP, Head of IR/PR/Marketing

(858) 900-2682

IR@ArcturusRx.com

Kendall Investor Relations

Carlo Tanzi, Ph.D.

(617) 914-0008

ctanzi@kendallir.com

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.